Abstract
To avoid ambiguity, the following emendations are advocated:
-
(1)
2H, in place of H2, to designate the second histamine receptor;
-
(2)
HN-2, in place of HN2, to designate mechlorethamine (MBA);
-
(3)
‘pre-drug’, in place of ‘pro-drug’, to describe molecular species which must undergo biotransformation before yielding an effective drug.
References
A. S. F. Ash andH. O. Schild,Receptors Mediating some Actions of Histamine, Br. J. Pharmac.27, 427 (1966).
L. W. Chakrin, R. D. Krell, J. Mengel, D. Young, C. Zaher andJ. R. Wardell, Jr.,Effect of a Histamine H 2 -Receptor Antagonist on Immunologically Induced Mediator Release in vitro, Agents and Actions4, 297 (1974).
A. Farkas,Orthohydrogen, Parahydrogen and Heavy hydrogen (Cambridge University Press 1935).
G. D. Snell, P. Smith andF. Gabrielson,Analysis of the Histocompatability-2 Locus in the Mouse, J. Nat. Cancer Inst.14, 457 (1953).
F. S. Philips,Recent contributions to the pharmacology of bis (2-haloethyl)amines and sulfides, Pharmac. Rev.2, 281 (1950).
N. J. Harper,Drug Latentiation, in:Fortschritte der Arzneimittelforschung, vol. 4 (Ed. E. Jucker; Birkhäuser Verlag, Basel 1962), p. 221.
A. Albert,Selective Toxicity, 5th ed. (Chapman & Hall, London 1973), p. 50–57.
Symposium,Pro-drugs as Novel Drug Delivery Systems, Abstr. Am. Chem. Soc. meeting, Med. Chem. Div., Atlantic City, Sept. 1974.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Whitehouse, M.W. Problems of nomenclature III: ambiguous abbreviations and catchwords. Agents and Actions 5, 181–182 (1975). https://doi.org/10.1007/BF02026433
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02026433